Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | CFD | P00746 | 6/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294373 | 1.00 | P4HB (0.54) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL5624264 | 1.00 | P4HB (0.54) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL5623207 | 1.00 | P4HB (0.54) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL22512607 | 0.92 | P4HB (0.54) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL12596879 | 0.92 | P4HB (0.54) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL14499186 | 0.92 | P4HB (0.53) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL12596916 | 0.92 | P4HB (0.53) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL13822019 | 0.91 | P4HB (0.55) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL31238398 | 0.91 | P4HB (0.55) | P4HBHSP90AA1KDM4EALDH1A1LMNA | |
| SCHEMBL12596987 | 0.91 | P4HB (0.55) | P4HBHSP90AA1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235578-B2 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-06-26 | — | — | US | claimed |
| EP-0938474-B1 | CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS | AUCKLAND UNISERVICES LTD (NZ) | 2005-11-23 | — | — | EP | claimed |
| US-20050148651-A1 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-07-07 | — | — | US | claimed |
| WO-2003097635-A1 | PROCESSES FOR PREPARING 3-SUBSTITUTED 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H-[RING FUSED INDOL-5-YL(AMINE-DERIVED)] COMPOUNDS AND ANALOGUES THEREOF, AND TO PRODUCTS OBTAINED THEREFROM | AUCKLAND UNISERVICES LIMITED (NZ) | 2003-11-27 | — | — | WO | claimed |
| US-6130237-A | Condensed N-aclyindoles as antitumor agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-10 | — | — | US | claimed |
| WO-2020157662-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-08-06 | — | — | WO | disclosed |
| EP-2830614-B1 | CYCLIC PRODRUGS OF DUOCARMYCIN ANALOGS | SCRIPPS RESEARCH INST (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9139596-B2 | Cyclic prodrugs of duocarmycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150057270-A1 | CYCLIC PRODRUGS OF DUOCARMYCIN ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| US-7553816-B2 | p-amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7235578-B2 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-06-26 | — | — | US | disclosed |
| EP-1320522-B8 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | LEE MOSES (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050148651-A1 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-07-07 | — | — | US | disclosed |
| US-6660742-B2 | Alkylation therapy; anticancer agent | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1320522-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | disclosed |
| WO-2002030894-A2 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-18 | — | — | WO | disclosed |
| US-6130237-A | Condensed N-aclyindoles as antitumor agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148651-A1 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom | CBR3, ANPEP, CBR1 | P4HB 344/4885HSP90AA1 3630/4885KDM4E 661/4885 |
| US-20150057270-A1 | CYCLIC PRODRUGS OF DUOCARMYCIN ANALOGS | DCK, DCTD, DUT | P4HB 536/4885HSP90AA1 2627/4885KDM4E 902/4885 |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | P4HB 692/4885HSP90AA1 3401/4885KDM4E 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.